Entheon Biomedical Partners with Wavepaths for Upcoming Observational Study
Vancouver, British Columbia–(Newsfile Corp. – February 16, 2022) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon“or the”Society“), a company focused on the research and development of psychedelic drugs and advanced biomarkers to provide personalized treatment for addictive disorders, is launching the next observational trial EBIQ-101 (“EBIQ-101“or the”Trial“) in partnership with Wavepaths LLC (“Wave paths“). The study is taking place at Heading Health LLC (“Health section”) with Dr. Steve Levine, MD, as principal investigator. Recruitment for EBIQ-101 is complete and the first patient dose is expected later this week.
Entheon, the sponsor of EBIQ-101, is thrilled to partner with Wavepaths, a generative music technology company that, in part, provides music experiences for psychedelic therapy. Wavepaths’ technology allows the music experience to be fully personalized to each patient’s preferences and needs and adapted live to meet those needs as they evolve during a therapy session. . Integrating neuroscience, machine learning, music theory, and experience design to optimize music experiences for therapeutic outcomes, Wavepaths will implement its platform in the EBIQ-101 study.
Wavepaths will also gather scientific evidence on how changes in musical structure (such as depth, loudness, etc.) correlate with EEG measurements of neurological activity during ketamine administration. The Psychedelic Music Questionnaire, developed by Wavepaths, will also be used in the study, which will help Wavepaths optimize its music system to create desired brain changes in patients receiving ketamine treatment for depression.
“In addition to supporting the study itself, Wavepaths hopes the results will demonstrate how Wavepaths’ adaptive music platform can be used to support psychedelic therapy in a clinical trial,” said Mendel Kaelen, Founder. and CEO of Wavepaths. “Because Wavepaths can be used to reach specific emotional states and intensity levels, it allows for variation from session to session while maintaining reliability.”
To learn more about Wavepaths, please visit www.wavepaths.com.
“Music has long been considered a crucial part of the psychedelic therapy experience, so partnering with Wavepaths on this study is a great opportunity to determine and further discover the effect of audio in therapeutic settings” , said Timothy Ko, CEO of Entheon. “As a cutting-edge sound engineering and technology company, Wavepaths has pioneered the development of augmented and adaptive soundscapes that can serve as a therapeutic modality in themselves. There is no other company we would prefer have to support this study and its participants.”
EBIQ-101, an open-label observational study, is being conducted by Heading Health, LLC (“Heading Health”) to observe the EEG pattern of participants treated with intramuscular ketamine for treatment-resistant major depressive disorder. The data collected will be used to inform understanding of changes in brain activity in response to ketamine.
For more information about the study, please visit: https://clinicaltrials.gov/ct2/show/NCT05095792?term=EBIQ-101.
In addition, participants’ genetic markers will be compared, while data on the impact of genetic markers and response to ketamine will also be analyzed. The results of the study will help advance Entheon’s biomarker program to characterize various medication states and mental health disorders.
About Entheon Biomedical Corp.
Entheon is a biomedical company focused on the research and development of advanced psychedelic drugs and biomarkers to provide personalized treatment for addictive disorders. Entheon is comprised of three divisions, Entheon RX™, focused on the development of therapeutic drugs using N,N-dimethyltryptamine (DMT) as a pharmacological reference; Entheon ID™, focused on the identification, analysis and predictive use of EEG biomarkers and genetics in drug therapy selection and management; and Entheon IQ™, focused on developing treatment algorithms by analyzing patient data. Subject to obtaining all required regulatory approvals and permits, Entheon intends to generate revenue from the sale of its DMT products to licensed physicians, clinics and psychiatrists in the United States, certain countries of the European Union and throughout Canada.
For more information, please contact the Company at:
Entheon Biomedical Corp.
Joseph Cullen, Investor Relations
Phone: +1 (778) 919-8615
For Entheon media inquiries, please contact Elizabeth Glassen of BlueSky Communications at:
Blue Sky Communications
Elizabeth Glassen, Account Manager
Phone: +1 (647) 309-0141
Caution regarding forward-looking information
This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Specifically, and without limitation, this press release contains forward-looking statements and information relating to the timing of the launch of EBIQ-101, the Company’s planned clinical trial, trial and study results, collaboration expected with Wavepaths, and expected outcome and timing of outcomes and other issues. Forward-looking statements and information are based on certain key expectations and assumptions made by the Company’s management, including, but not limited to, assumptions relating to the continued impact and status of COVID-19 on the workforce of the Company and the planned research activities, that the general economic and political conditions will remain the same, that the Company will be able to prepare the submission and complete the initiation of the site and the initial selection within the expected time frame, that the studies preclinical studies will be completed on schedule, expected results of collaboration with Wavepaths, stability of applicable laws and regulations. Although the Company’s management believes that the expectations and assumptions on which these forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information as no assurance can be given that they will prove to be be correct.
Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of the Company’s management regarding the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Because forward-looking statements and information address future events and conditions, they, by their very nature, involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, an increase in the number of COVID cases worldwide, a negative impact of COVID on the research activities of the Company and its research partners, the inability to prepare the timely IMPD submission, difficulties in subject recruitment, initial screening or site initiation, delays in the timing of clinical trials planned by the Company due to other unknown uncertainties and adverse changes in laws and applicable regulations. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this press release. Readers are cautioned that the above list of factors is not exhaustive. The forward-looking statements and information contained in this press release are made as of the date hereof, and no obligation is given to publicly update or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless required by applicable securities laws. Forward-looking statements or information contained in this press release are expressly qualified by this cautionary statement.
Neither CSE nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/113958